ASN 002Alternative Names: ASN002
Latest Information Update: 17 Mar 2017
At a glance
- Originator Asana BioSciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Solid tumours
- Preclinical Atopic dermatitis; Rheumatoid arthritis